RxDoctor Payments Data

Maureen Eisenberg, DO

Family Medicine · Hanover, PANPI 1336148121

Payments from drug & device makers

$10,806in general payments, 2019–2025

Across 776 payments — averaging $13.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • AbbVie$1K
  • GSK$1K
  • Boehringer Ingelheim$772
  • AstraZeneca$709
  • Lilly USA, LLC$650
  • plus $4K from 39 others

What the payments were for

  • Food & beverage$10,73599%
  • Education$711%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$10,806 in reported general payments places this provider in the 90th percentile of 4,967 family medicine providers in Pennsylvania.

See all family medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$365,498
Medicare patients
497
Services billed
9,500

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban123$113,848
OzempicSemaglutide41$58,215
JardianceEmpagliflozin26$37,424
Trelegy ElliptaFluticasone/Umeclidin/Vilanter47$36,138
TrulicityDulaglutide15$34,346
MyrbetriqMirabegron22$23,024
MounjaroTirzepatide22$22,654
Breo ElliptaFluticasone/Vilanterol25$12,265
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog20$11,089
Tresiba Flextouch U-100Insulin Degludec12$9,763
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr17$8,143
VascepaIcosapent Ethyl21$6,977
LyricaPregabalin11$4,081
LumiganBimatoprost11$3,786
Atorvastatin Calcium450$3,420

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Lyrica$629$117,928134 claims
Novo NordiskOzempic$1,755$58,21541 claims
Lilly USA, LLCTrulicity, Mounjaro$650$57,00037 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$1,193$56,54589 claims
Boehringer IngelheimJardiance$772$37,42426 claims
Astellas Pharma US IncMyrbetriq$290$23,02422 claims
AbbVieLumigan, Synthroid$1,237$5,71641 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,967 family medicine providers in Pennsylvania.

Other family medicine in Hanover

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →